SG11202110085TA - Btk inhibitor ring derivative, preparation method therefor and pharmaceutical application thereof - Google Patents

Btk inhibitor ring derivative, preparation method therefor and pharmaceutical application thereof

Info

Publication number
SG11202110085TA
SG11202110085TA SG11202110085TA SG11202110085TA SG11202110085TA SG 11202110085T A SG11202110085T A SG 11202110085TA SG 11202110085T A SG11202110085T A SG 11202110085TA SG 11202110085T A SG11202110085T A SG 11202110085TA SG 11202110085T A SG11202110085T A SG 11202110085TA
Authority
SG
Singapore
Prior art keywords
preparation
method therefor
btk inhibitor
ring derivative
pharmaceutical application
Prior art date
Application number
SG11202110085TA
Inventor
Chen Zhang
Yuting Liao
Jianmin Wang
Guozhi Zhu
Fei Ye
Pingming Tang
Xiaogang Chen
Zhenggang Huang
Shoutao Wu
Yao Li
Pangke Yan
Original Assignee
Sichuan Haisco Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Haisco Pharmaceutical Co Ltd filed Critical Sichuan Haisco Pharmaceutical Co Ltd
Publication of SG11202110085TA publication Critical patent/SG11202110085TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11202110085TA 2019-05-31 2020-05-29 Btk inhibitor ring derivative, preparation method therefor and pharmaceutical application thereof SG11202110085TA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201910454977 2019-05-31
CN201910706239 2019-08-02
CN201910997078 2019-10-25
CN201911291561 2019-12-16
PCT/CN2020/093455 WO2020239103A1 (en) 2019-05-31 2020-05-29 Btk inhibitor ring derivative, preparation method therefor and pharmaceutical application thereof

Publications (1)

Publication Number Publication Date
SG11202110085TA true SG11202110085TA (en) 2021-10-28

Family

ID=73553513

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202110085TA SG11202110085TA (en) 2019-05-31 2020-05-29 Btk inhibitor ring derivative, preparation method therefor and pharmaceutical application thereof

Country Status (13)

Country Link
US (1) US11542266B1 (en)
EP (1) EP3978496A4 (en)
JP (1) JP2022534650A (en)
KR (1) KR20220016049A (en)
CN (1) CN113544130B (en)
AU (1) AU2020281410A1 (en)
BR (1) BR112021024131A2 (en)
CA (1) CA3133004A1 (en)
IL (1) IL287332A (en)
MX (1) MX2021012756A (en)
SG (1) SG11202110085TA (en)
TW (1) TWI762939B (en)
WO (1) WO2020239103A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022534650A (en) * 2019-05-31 2022-08-03 海思科医▲薬▼有限公司 BTK inhibitor ring derivative, its preparation method and its pharmaceutical application
CN115052594A (en) 2020-01-29 2022-09-13 福宏治疗公司 Compounds and uses thereof
AU2020436612A1 (en) 2020-03-16 2022-09-01 Flash Therapeutics, Llc Compounds for treating or inhibiting recurrence of acute myeloid leukemia
WO2022007824A1 (en) 2020-07-07 2022-01-13 四川海思科制药有限公司 Compound having btk kinase degrading activity, and preparation method and pharmaceutical use therefor
US11787800B2 (en) 2020-07-29 2023-10-17 Foghorn Therapeutics Inc. BRD9 degraders and uses thereof
KR20230091088A (en) * 2020-09-09 2023-06-22 하이스코 파마수티컬즈 피티이. 엘티디. Salts of compounds for degrading BTK, crystalline forms thereof, and uses thereof in medicaments
WO2022111449A1 (en) * 2020-11-25 2022-06-02 四川海思科制药有限公司 Preparation method for btk degradation agent
CN116323594A (en) * 2020-11-25 2023-06-23 四川海思科制药有限公司 Preparation method of BTK degradation agent
US20240002387A1 (en) * 2020-11-25 2024-01-04 Haisco Pharmaceuticals Pte. Ltd. Method for preparing btk degrading agent
CN117377675A (en) * 2021-06-01 2024-01-09 正大天晴药业集团股份有限公司 Bruton's tyrosine kinase degradation agent containing parallel ring or spiro ring
CN115521313B (en) * 2021-06-24 2023-11-03 山东大学 Compound for degrading BTK protein and preparation method and application thereof
US11767330B2 (en) 2021-07-06 2023-09-26 Foghorn Therapeutics Inc. Citrate salt, pharmaceutical compositions, and methods of making and using the same
TW202321219A (en) 2021-08-11 2023-06-01 大陸商四川海思科製藥有限公司 Heterocyclic derivative, and composition and pharmaceutical use thereof
US20230137175A1 (en) * 2021-08-17 2023-05-04 Endotarget Inc. Compounds and methods for the targeted degradation of bruton's tyrosine kinase
WO2023072270A1 (en) * 2021-10-29 2023-05-04 百极弘烨(南通)医药科技有限公司 Protac compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof
WO2023125907A1 (en) * 2021-12-30 2023-07-06 Beigene, Ltd. Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6921763B2 (en) * 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
US20050256309A1 (en) * 2004-05-12 2005-11-17 Altenbach Robert J Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands
AR065810A1 (en) * 2007-03-20 2009-07-01 Celgene Corp DERIVATIVES OF ISOINDOLIN 4'-O-SUBSTITUTES, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND AND USES THEMSELVES IN THE TREATMENT OF CANCER AND IN OTHER DISORDERS WHERE THE CONTROL OF ANGIOGENESIS OR THE INHIBITION OF CYTOQUINES, INCLUDING TNF-NUTS, INCLUDES.
US7718662B1 (en) * 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
WO2011094290A1 (en) * 2010-01-27 2011-08-04 Vertex Pharmaceuticals Incorporated Pyrazolopyrimidine kinase inhibitors
LT2975042T (en) * 2010-06-23 2019-01-25 Hanmi Science Co., Ltd. Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
WO2012096928A2 (en) * 2011-01-10 2012-07-19 Glaxosmithkline Llc Pyrimidinone derivatives as fatty acid synthase inhibitors
EP2687511A1 (en) * 2012-07-17 2014-01-22 Zedira GmbH Pyridinone derivatives as tissue transglutaminase inhibitors
CN105308038B (en) * 2013-04-30 2018-05-29 葛兰素史密斯克莱知识产权（第2 号）有限公司 The inhibitor of Zeste enhancers homologue 2
EP3019489A4 (en) * 2013-07-11 2016-12-28 Betta Pharmaceuticals Co Ltd Protein tyrosine kinase modulators and methods of use
WO2016004272A1 (en) * 2014-07-02 2016-01-07 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
CN104530046B (en) * 2014-12-10 2016-08-24 广东东阳光药业有限公司 Diaza spiro compounds and the application in medicine thereof
WO2017029601A1 (en) * 2015-08-17 2017-02-23 Lupin Limited Heteroaryl derivatives as parp inhibitors
CN107849047B (en) * 2015-09-28 2021-01-15 四川海思科制药有限公司 Biphenyl derivative, preparation method and medical application thereof
GB201517217D0 (en) * 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
CA3001799A1 (en) * 2015-10-21 2017-04-27 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
WO2017134685A2 (en) * 2016-02-02 2017-08-10 Sun Pharma Advanced Research Company Limited Novel hydrazino compounds as btk inhibitors
CN115746000A (en) 2016-03-11 2023-03-07 嘉兴和剂药业有限公司 Compounds and methods for modulating bruton's tyrosine kinase
WO2017197055A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
AU2017314178B2 (en) 2016-08-16 2021-11-18 Beigene Switzerland Gmbh Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
GB201614134D0 (en) 2016-08-18 2016-10-05 Glaxosmithkline Ip Dev Ltd Novel compounds
JP7009466B2 (en) 2016-10-11 2022-02-10 アルビナス・オペレーションズ・インコーポレイテッド Compounds and methods for targeted degradation of androgen receptors
CN106831787B (en) * 2017-01-20 2018-10-23 成都倍特药业有限公司 Compound and its preparation method and application as bruton's tyrosine kinase inhibitor
TWI754011B (en) * 2017-02-24 2022-02-01 美商基利科學股份有限公司 Inhibitors of bruton's tyrosine kinase
CN109422752B (en) * 2017-09-03 2023-04-07 上海美志医药科技有限公司 Compound with functions of inhibiting and degrading Bruton tyrosine protein kinase Btk activity
CN109422696B (en) * 2017-09-04 2020-10-30 北京睿熙生物科技有限公司 Inhibitors of bruton's tyrosine kinase
WO2019127008A1 (en) * 2017-12-26 2019-07-04 清华大学 Compound for targeted degradation of btk and application thereof
CN108191871B (en) * 2018-01-02 2020-02-18 成都倍特药业有限公司 Novel Bruton's tyrosine kinase inhibitor and preparation method and application thereof
JP2022534650A (en) * 2019-05-31 2022-08-03 海思科医▲薬▼有限公司 BTK inhibitor ring derivative, its preparation method and its pharmaceutical application

Also Published As

Publication number Publication date
CN113544130A (en) 2021-10-22
TW202110825A (en) 2021-03-16
BR112021024131A2 (en) 2022-01-11
CA3133004A1 (en) 2020-12-03
CN113544130B (en) 2024-01-09
AU2020281410A1 (en) 2021-10-07
IL287332A (en) 2021-12-01
MX2021012756A (en) 2022-04-18
EP3978496A4 (en) 2022-08-17
TWI762939B (en) 2022-05-01
JP2022534650A (en) 2022-08-03
US11542266B1 (en) 2023-01-03
EP3978496A1 (en) 2022-04-06
WO2020239103A1 (en) 2020-12-03
KR20220016049A (en) 2022-02-08

Similar Documents

Publication Publication Date Title
IL287332A (en) Btk inhibitor ring derivative, preparation method therefor and pharmaceutical application thereof
SG11202006409TA (en) Biaryl derivative, preparation method therefor and pharmaceutical use thereof
SG11202105850YA (en) Diphenyl-like compound, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and uses thereof
EP3486242A4 (en) Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof
EP3275867A4 (en) Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof
EP3632907A4 (en) N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof
EP3805231A4 (en) Inhibitor containing tricyclic derivative, preparation method therefor, and application thereof
EP4056571A4 (en) Tricyclic dihydroimidazopyrimidone derivative, preparation method therefor, pharmaceutical composition and use thereof
IL276244A (en) Ophthalmic pharmaceutical composition, preparation method therefor and application thereof
ZA202202932B (en) Fxia inhibitors and preparation method therefor and pharmaceutical use thereof
EP3653202A4 (en) Pharmaceutical preparation and preparation method therefor
EP4079734A4 (en) Triazolopyridazine derivative, preparation method therefor, pharmaceutical composition thereof, and use thereof
EP3450450A4 (en) Vancomycin derivative, preparation method, pharmaceutical composition and use thereof
EP3406606A4 (en) Nitrogenous heterocyclic amide derivative, preparation method thereof, and pharmaceutical application
IL276311A (en) Methyllactam ring compound and pharmaceutical use thereof
EP3988547A4 (en) Indazole derivative, preparation method therefor, and pharmaceutical application thereof
IL291557A (en) An antibody, a pharmaceutical composition, and a method
EP3730484A4 (en) Indoleamine-2,3-dioxygenase inhibitor, preparation method therefor, and application thereof
IL282218A (en) New amino-pyrimidonyl-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
EP4053311A4 (en) Half-life extension drug and library thereof, and preparation method and application thereof
EP3851438A4 (en) Btk inhibitor, pharmaceutically acceptable salt, polymorph and application thereof
EP3805212A4 (en) 3-oxazolinone compound, preparation method therefor and pharmaceutical application thereof
EP3858812A4 (en) Mdm2 inhibitor, preparation method therefor, pharmaceutical composition thereof, and use thereof
EP4137124A4 (en) Solid pharmaceutical preparation, preparation method therefor and use thereof
EP4071170A4 (en) Pharmaceutical composition, preparation method therefor and use thereof